Work

Guselkumab for the treatment of pyoderma gangrenosum

Year: 2024

Type: article

Abstract: Pyoderma gangrenosum (PG) is a complex disease with limited therapeutic options. Here we report the use of higher dose of guselkumab, a monoclonal antibody targeting interleukin (IL‐) 23, in the treatment of PG in a medically complex patient. This case contributes additional evidence supporting the potential effectiveness of guselkumab in the treatment of PG and highlights the necessity for larger studies to confirm these findings.

Source: JEADV Clinical Practice

DOI: 10.1002/jvc2.547

Authors: Sera Sarsam, Holly Sexton, Jenny Nicolopoulos, Con Dolianitis

Institutions: The Royal Melbourne Hospital, The University of Melbourne

Language: English

Topic: Autoimmune and Inflammatory Disorders

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,700